Orthocell's (ASX:OCC) recently secured FDA clearance for its nerve repair product, Remplir marked a "major milestone" and "de-risking event" for the company, said Euroz Hartley in a Monday note.
The company received regulatory clearance from the US Food and Drug Administration for the product, under the 510(k) pathway, allowing sales in the US market, according to a Friday filing with the Australian bourse.
The research firm noted that the approval enables Remplir to access the $1.6 billion US nerve repair market.
Euroz Hartleys raised its price target from AU$0.97 to AU$1.19 while maintaining a hold rating.
The company's shares fell 4% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.